Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration

Liang,Guanzhao; Ding,Minglei; Lu,Haitao; Cao,Na; Niu,Yandong; Gao,Yang; Lu,Jie

doi:10.3892/ol.2015.3475

Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration

Authors:
- Guanzhao Liang
- Minglei Ding
- Haitao Lu
- Na Cao
- Yandong Niu
- Yang Gao
- Jie Lu
View Affiliations

Affiliations: Department of Dermatology, The Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, P.R. China
Published online on: July 8, 2015 https://doi.org/10.3892/ol.2015.3475
Pages: 1527-1532

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant melanoma is a highly metastatic cancer, and has a poor prognosis once metastasis has occurred. E-cadherin downregulation is associated with a poorer prognosis in various types of cancer, including lung, ovarian, cervical and prostate. In the majority of cancer cell lines, E‑cadherin upregulation inhibits cell motility, migration and invasiveness, and reduces tumor metastasis in in vivo models. In the present study, the inhibitory effects of metformin on the motility, invasion and migration of the B16F10 murine melanoma cell line, and the possible molecular mechanisms underlying this effect were investigated. B16F10 cells were treated with various concentrations of metformin for 24 h and their motility, migration and invasion were tested using a wound‑healing assay, a migration assay and a matrigel invasion assay, respectively. Furthermore, the expression of E‑cadherin was measured by immunocytochemistry, western blotting and reverse transcription‑quantitative polymerase chain reaction. The results showed that metformin effectively upregulated the expression of E‑cadherin, and inhibited B16F10 cell motility, migration and invasion, in a dose‑dependent manner. This suggested that the inhibition of motility, migration and invasion of B16F10 cells by metformin may be associated with the upregulation of E‑cadherin expression, indicating that metformin may have a role in the treatment of melanoma.

View Figures

View References

1	Shore RN, Shore P, Monahan NM and Sundeen J: Serial screening for melanoma: Measures and strategies that have consistently achieved early detection and cure. J Drugs Dermatol. 10:244–252. 2011.PubMed/NCBI
2	Boyle GM: Therapy for metastatic melanoma: An overview and update. Expert Rev Anticancer Ther. 11:725–737. 2011. View Article : Google Scholar : PubMed/NCBI
3	MacKie RM, Hauschild A and Eggermont AM: Epidemiology of invasive cutaneous melanoma. Ann Oncol. 20 (Suppl 6):vi1–vi7. 2009. View Article : Google Scholar : PubMed/NCBI
4	Houghton AN and Polsky D: Focus on melanoma. Cancer Cell. 2:275–278. 2002. View Article : Google Scholar : PubMed/NCBI
5	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
6	Hollier BG, Evans K and Mani SA: The epithelial-to-mesenchymal transition and cancer stem cells: A coalition against cancer therapies. J Mammary Gland Biol Neoplasia. 14:29–43. 2009. View Article : Google Scholar : PubMed/NCBI
7	Zeisberg M and Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437. 2009. View Article : Google Scholar : PubMed/NCBI
8	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
9	Hsu MY, Meier FE, Nesbit M, Hsu JY, Van Belle P, Elder DE and Herlyn M: E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol. 156:1515–1525. 2000. View Article : Google Scholar : PubMed/NCBI
10	Kourelis TV and Siegel RD: Metformin and cancer: New applications for an old drug. Med Oncol. 29:1314–1327. 2012. View Article : Google Scholar : PubMed/NCBI
11	Ben Sahra I, Le Marchand-brustel Y, Tanti JF and Bost F: Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010. View Article : Google Scholar : PubMed/NCBI
12	Pollak M: Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila). 3:1060–1065. 2010. View Article : Google Scholar : PubMed/NCBI
13	Noto H, Goto A, Tsujimoto T and Noda M: Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS One. 7:e334112012. View Article : Google Scholar
14	Woodard J and Platanias LC: AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem Biophys Res Commun. 398:135–139. 2010. View Article : Google Scholar : PubMed/NCBI
15	Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N, Sumarac-Dumanovic M, Micic D and Trajkovic V: In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol. 668:373–382. 2011. View Article : Google Scholar : PubMed/NCBI
16	Niehr F, von EE, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, et al: Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 9:762011. View Article : Google Scholar : PubMed/NCBI
17	Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, et al: Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2:e1992011. View Article : Google Scholar : PubMed/NCBI
18	Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, et al: Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther. 12:1605–1615. 2013. View Article : Google Scholar : PubMed/NCBI
19	Liang CC, Park AY and Guan JL: In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
20	Andújar-Plata P, Pi-Sunyer X and Laferrère B: Metformin effects revisited. Diabetes Res Clin Pract. 95:1–9. 2012. View Article : Google Scholar : PubMed/NCBI
21	Cerezo M, Tomic T, Ballotti R and Rocchi S: Is it time to test biguanide metformin in the treatment of melanoma? Pigment Cell Melanoma Res. 28:8–20. 2014. View Article : Google Scholar : PubMed/NCBI
22	Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y and Bost F: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
24	Algire C, Zakikhani M, Blouin MJ, Shuai JH and Pollak M: Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer. 15:833–839. 2008. View Article : Google Scholar : PubMed/NCBI
25	Wang LW, Li ZS, Zou DW, Jin ZD, Gao J and Xu GM: Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol. 14:7192–7198. 2008. View Article : Google Scholar : PubMed/NCBI
26	Takeichi M: Cadherins in cancer: Implications for invasion and metastasis. Curr Opin Cell Biol. 5:806–811. 1993. View Article : Google Scholar : PubMed/NCBI
27	Christofori G and Semb H: The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci. 24:73–76. 1999. View Article : Google Scholar : PubMed/NCBI
28	Rattan R, Ali Fehmi R and Munkarah A: Metformin: An emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol. 2012:9281272012. View Article : Google Scholar : PubMed/NCBI
29	Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G and Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68:989–997. 2008. View Article : Google Scholar : PubMed/NCBI
30	Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:927–939. 2004. View Article : Google Scholar : PubMed/NCBI
31	Birchmeier W and Behrens J: Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1198:11–26. 1994.PubMed/NCBI
32	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–148. 2009. View Article : Google Scholar : PubMed/NCBI
33	Perl AK, Wilgenbus P, Dahl U, Semb H and Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 392:190–193. 1998. View Article : Google Scholar : PubMed/NCBI
34	Nakamura M and Tokura Y: Epithelial-mesenchymal transition in the skin. J Dermatol Sci. 61:7–13. 2011. View Article : Google Scholar : PubMed/NCBI
35	Tang A, Eller MS, Hara M, Yaar M, Hirohashi S and Gilchrest BA: E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J Cell Sci. 107:983–992. 1994.PubMed/NCBI